Classification
Compound class	Synthetic organic
Approved drug?	Yes (source: EMA & FDA (2013))

IUPAC Name

(2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-oxolan-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide

International Nonproprietary Names
INN number	INN
9230	afatinib

Synonyms

BIBW2992

Gilotrif®

Database Links
CAS Registry No.	850140-72-6
ChEMBL Ligand	CHEMBL1173655
DrugBank Ligand	DB08916
PubChem CID	10184653
RCSB PDB Ligand	0WM
Search Google for chemical match using the InChIKey	ULXXDDBFHOBEHA-CWDCEQMOSA-N
Search Google for chemicals with the same backbone	ULXXDDBFHOBEHA
Search PubMed clinical trials	afatinib
Search PubMed titles	afatinib
Search PubMed titles/abstracts	afatinib
Wikipedia	Afatinib

Comments

Afatinib is a second-generation, irreversible, covalently-bound EGFR tyrosine kinase inhibitor. It potently and selectively inhibits EGFR and Erbb2 [3,5,7]. Although afatinib demonstrates improved activity against the gatekeeper EGFR T790M resistance mutation, it is equally potent against the wild-type receptor, leading to dose-limiting toxicities and a narrow safety window [8]. Third generation, wild-type sparing inhibitors such as nazartinib are in development to circumvent this problem [4].